Metastatic Urothelial Carcinoma Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Metastatic Urothelial Carcinoma Research. Learn more about our innovative pipeline today! @ Metastatic Urothelial Carcinoma Pipeline Outlook
Key Takeaways from the Metastatic Urothelial Carcinoma Pipeline Report
In July 2025, Inovio Pharmaceuticals announced a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa).
In July 2025, Merck Sharp & Dohme LLC conducted a substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
In July 2025, Seagen organized a study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
DelveInsight's Metastatic Urothelial Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Metastatic Urothelial Carcinoma treatment.
The leading Metastatic Urothelial Carcinoma Companies such as PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Promising Metastatic Urothelial Carcinoma Pipeline Therapies such as BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others.
Stay informed about the cutting-edge advancements in Metastatic Urothelial Carcinoma treatments. Download for updates and be a part of the revolution in oncology Care @ Metastatic Urothelial Carcinoma Clinical Trials Assessment
Metastatic Urothelial Carcinoma Emerging Drugs Profile
MFA 370: Ectin Research AG
Urothelial bladder cancer is one of the world's most aggressive cancers, current treatments can be tough to tolerate. MFA-370 is planned to be a simple oral tablet developed to eliminate tumors safely, with few if any side effects. MFA-370 is a combination of a medication from that substance family, together with one other standard, well-established drug. Both are tried, tested and trusted treatments that have already undergone large-scale clinical trials. It already demonstrated efficacy in preclinical results and 'patient zero' case. In addition to MFA-370 showing positive preclinical results in metastatic urothelial bladder cancer, it has also eliminated prostate, breast and colorectal cancer cells in preclinical tests too. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
XL 092: Exelixis
XL092 is a next-generation oral TKI that builds on our extensive experience with cabozantinib. XL092 also targets VEGF receptors, MET, TAM kinases and other kinases implicated in cancer's growth and spread. In preclinical tumor models, XL092 showed excellent activity as a single agent and in combination with ICIs. XL092 also has an optimized pharmacokinetic profile aimed at facilitating adverse event management in the clinic. XL092 is the first new Exelixis-discovered compound to come out of the company's reinitiated drug discovery activities, which entered phase 1 clinical development in 2019. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
Lurbinectedin: PharmaMar
Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds. Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Metastatic Urothelial Carcinoma.
The Metastatic Urothelial Carcinoma Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Urothelial Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Urothelial Carcinoma Treatment.
Metastatic Urothelial Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Urothelial Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Urothelial Carcinoma market.
Learn more about Metastatic Urothelial Carcinoma Drugs opportunities in our groundbreaking Metastatic Urothelial Carcinoma research and development projects @ Metastatic Urothelial Carcinoma Unmet Needs
Metastatic Urothelial Carcinoma Companies
PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Metastatic Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Metastatic Urothelial Carcinoma Products have been categorized under various Molecule types such as
Oligonucleotide
Peptide
Small molecule
Discover the latest advancements in Metastatic Urothelial Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Metastatic Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Urothelial Carcinoma Pipeline Report
Coverage- Global
Metastatic Urothelial Carcinoma Companies- PharmaMar, Ectin Research AG, Exelixis, Eli Lilly and Company, Merck Sharp & Dohme LLC, Astellas Pharma Inc, Seagen Inc., Shanghai Miracogen Inc., Advaxis, Inc. and others.
Metastatic Urothelial Carcinoma Pipeline Therapies- BT8009, Olaparib, Enfortumab vedotin, Nivolumab, Gemcitabine, Carboplatin, Sacituzumab Govitecan-hziy, Pembrolizumab, Cisplatin, Ipilimumab, Tremelimumab and others.
Metastatic Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Urothelial Carcinoma Pipeline on our website @ Metastatic Urothelial Carcinoma Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Metastatic Urothelial Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Urothelial Carcinoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Lurbinectedin: PharmaMar
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
XL 092: Exelixis
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Inactive Products
Metastatic Urothelial Carcinoma Key Companies
Metastatic Urothelial Carcinoma Key Products
Metastatic Urothelial Carcinoma- Unmet Needs
Metastatic Urothelial Carcinoma- Market Drivers and Barriers
Metastatic Urothelial Carcinoma- Future Perspectives and Conclusion
Metastatic Urothelial Carcinoma Analyst Views
Metastatic Urothelial Carcinoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
22 minutes ago
- Globe and Mail
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action
New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Rocket Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. WHAT'S NEXT? If you suffered a loss in Rocket stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Globe and Mail
22 minutes ago
- Globe and Mail
RBGLY LAWSUIT ALERT: Levi & Korsinsky Notifies Reckitt Benckiser Group plc Investors - Lead Plaintiff Deadline August 4, 2025
New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Reckitt Benckiser Group plc (OTCQX: RBGLY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Reckitt Benckiser Group plc that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. WHAT'S NEXT? If you suffered a loss in Reckitt Benckiser Group plc stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
Globe and Mail
22 minutes ago
- Globe and Mail
Did You Lose Money on Red Cat Holdings, Inc. (RCAT)? Levi & Korsinsky Urges Investors to Act Before July 22, 2025
New York, New York--(Newsfile Corp. - July 18, 2025) - If you suffered a loss on your Red Cat Holdings, Inc. (NASDAQ: RCAT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Red Cat Holdings, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 18, 2022 and January 15, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Salt Lake City Facility's production capacity, and defendants' progress in developing the same, was overstated; (ii) the overall value of the U.S. Army's Short Range Reconnaissance Program of Record Tranche 2 contract was overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Red Cat Holdings, Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
